Protalix BioTherapeutics, Inc. Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax
Protalix BioTherapeutics, Inc. (PLX) reported Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax of $20.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Income Statement › Other Income
us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax · last filed 2026-03-18
- Protalix BioTherapeutics, Inc. other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2025 was $20.00K, a 11.11% increase from fiscal 2024.
- Protalix BioTherapeutics, Inc. other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2024 was $18.00K, a 64.00% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2023 was $50.00K.
- Protalix BioTherapeutics, Inc. other comprehensive income (loss), defined benefit plan, gain (loss), after reclassification adjustment, before tax for fiscal 2022 was -$3.00K, a 103.00% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax 12 month |
|---|---|
| 2025-12-31 | $20.00K 10-K · filed 2026-03-18 |
| 2024-12-31 | $18.00K 10-K · filed 2026-03-18 |
| 2023-12-31 | $50.00K 10-K · filed 2026-03-18 |
| 2022-12-31 | -$3.00K 10-K · filed 2025-03-17 |
| 2021-12-31 | $100.00K 10-K · filed 2024-03-14 |
| 2020-12-31 | $28.00K 10-K · filed 2023-02-27 |
| 2019-12-31 | $58.00K 10-K · filed 2022-03-31 |
| 2018-12-31 | $46.00K 10-K · filed 2021-03-30 |
| 2017-12-31 | $21.00K 10-K · filed 2020-03-12 |
| 2016-12-31 | -$7.00K 10-K · filed 2019-03-18 |
| 2015-12-31 | -$18.00K 10-K · filed 2018-03-06 |
| 2014-12-31 | $22.00K 10-K · filed 2017-03-16 |
| 2013-12-31 | $58.00K 10-K · filed 2016-03-08 |
| 2012-12-31 | $36.00K 10-K · filed 2015-03-12 |
| 2011-12-31 | $14.00K 10-K · filed 2014-03-13 |
| 2010-12-31 | $26.00K 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |